Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-020844
Filing Date
2025-02-14
Accepted
2025-02-14 13:15:56
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10138
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 252220
  Complete submission text file 0000950170-25-020844.txt   359567
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89959 | Film No.: 25626103
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201
Business Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201 214-364-2883
Ikarian Capital, LLC (Filed by) CIK: 0001778253 (see all company filings)

EIN.: 473466768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G